ResponderID

Products & Services

Information

ResponderID is the Genialis methodology for biomarker development it composes both a suite of proprietary AI technology and globally diverse patient data. ResponderID uses Genialis Foundation Model to predict patient response to therapy by developing biomarkers for all possible cancer targets
GenialisGenialis is the RNA biomarker company. We are creating a world where healthcare delivers the best possible outcomes for patients, their families and communities. Genialis develops and validates clinically actionable biomarkers informed by the world’s most ethnographically diverse cancer data sets to better predict patient responses and guide treatment decisions for targeted inhibitors, immunotherapies, and other emerging therapeutic classes. Genialis is trusted by pharma and diagnostics partners, and together, we are transforming medicine through data.

Log in